Patent Expiration of Drugs has led to a Slew of Asthma Pipeline Projects

Published Date : May 29, 2017

ALBANY, New York, May 29, 2017: has added a new market study to its repository, titled, “Asthma - Pipeline Review, H1 2017.” It furnishes thorough details of the therapeutics under development for asthma (respiratory), which is a chronic disease relating to the airways in the lungs. Some of the symptoms of asthma are shortness of breath, chest pains, and chronic coughing. Currently, treatment for asthma include inhaled corticosteroids, antihistamines, leukotriene modifiers, and decongestants. 

At present, North America is the dominant market for asthma treatment on account of the advanced healthcare infrastructure, continued drug innovation, a growing pool of elderly and asthma patients. North America is trailed by Europe, and Asia Pacific is another key market rising to a prominent position because of the increasing air pollution and rising number of smokers in the region. 

Currently, the global asthma treatment market is challenged by the growing number of patent expiration of drugs, increase in use of generic drugs, and expensive treatment. This has led to manufacturers, research and development institutes, universities, and healthcare facilities to focus on coming up with effective and relatively affordable treatments. As a result a lot of treatments are currently in the pipeline. 

The report throws light on such upcoming treatments for asthma. It provides a thorough reports of the route of administration (RoA), molecule type, stage of development, drug target, and mechanism of action (MoA). It also includes a description of the pharmacological action of the therapeutics, its research and development history, and the most recent news and press releases pertaining to it. 

For Sample Copy, click here: 

The report discusses the key players involved in therapeutic development for asthma and also brings to the fore inactive and discontinued projects. It covers therapeutics under development by companies /universities /institutes, the molecules developed by companies in pre-registration, phase III, phase II, phase I, IND/CTA filed, preclinical and discovery stages.

The current therapeutic development for asthma attempts to address the demand for novel biologic drugs and for personalized therapies to tackle extreme cases of asthma. A noticeable trend is the increasing number of mergers and acquisitions and collaborations among various institutes to come up with therapies that would help in timely detection and diagnosis at a relatively reduced cost. 

To present crucial information, the report provides a chart containing important statistics and figures, so that readers can easily distill crucial bits. The report will enable key players take corrective measures for pipeline projects by understanding asthma (respiratory) pipeline depth and develop and design in-licensing and out-licensing strategies by uncovering prospective partners working on potential projects. 

Some of the key players in the market are 4D Pharma PLC, AbbVie Inc, AB Science SA, Adamis Pharmaceuticals Corp, and AnaptysBio Inc. 

To order report Call Toll Free: 866-997-4948 or send an email on